Position in MRK
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$6,428,983
-$190,454 QoQ
Shares Held
50,031
-9.1% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.12%
of 13F equity value
Holder Rank
#932
of 3,769 holders
Holding Since
Dec 2023
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in MRK Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Brevan Howard Capital Management LP holds $180,596,811 across 9 Drug Manufacturers - General names. MRK ranks #7 (3.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
77,094 | $92,468,863 | |
| 2 | ABBV |
AbbVie Inc.
|
115,264 | $29,005,032 | |
| 3 | JNJ |
Johnson & Johnson
|
62,412 | $15,850,774 | |
| 4 | GILD |
Gilead Sciences, Inc.
|
123,329 | $15,581,385 | |
| 5 | BMY |
Bristol Myers Squibb Co
|
163,962 | $9,447,490 | |
| 6 | AMGN |
Amgen Inc
|
18,788 | $6,803,510 | |
| 7 | MRK |
Merck & Co., Inc.
This page
|
50,031 | $6,428,983 | |
| 8 | AZN |
Astrazeneca PLC
|
20,152 | $3,821,222 |
All Filings in MRK
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6,428,983 | 50,031 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $6,619,437 | 55,029 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $13,067,607 | 124,146 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $7,815,309 | 93,117 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $35,536,428 | 448,919 | Shares | Defined | 2025-08-14 | |
| 2024-12-31 | $8,221,822 | 82,648 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | $1,279,480 | 11,267 | Shares | Defined | 2024-11-14 | |
| 2024-03-31 | $13,047,611 | 98,883 | Shares | Defined | 2024-05-15 | |
| 2023-12-31 | $3,286,843 | 30,149 | Shares | Defined | 2024-02-14 | |
| No filing history on record for this holder in this stock. | ||||||